Shares of Tocagen (NASDAQ:TOCA) have received a consensus rating of “Buy” from the six ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $21.50.
A number of analysts have recently issued reports on TOCA shares. BidaskClub raised Tocagen from a “hold” rating to a “buy” rating in a research report on Saturday, March 17th. Zacks Investment Research raised Tocagen from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Wednesday, March 14th. Finally, ValuEngine raised Tocagen from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.
Shares of NASDAQ TOCA opened at $10.22 on Wednesday. Tocagen has a 1 year low of $8.60 and a 1 year high of $17.95. The stock has a market cap of $218.23 and a PE ratio of -3.84. The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.23 and a current ratio of 5.23.
Institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. bought a new stake in Tocagen in the fourth quarter valued at about $122,000. American International Group Inc. increased its holdings in Tocagen by 112.9% in the fourth quarter. American International Group Inc. now owns 11,995 shares of the company’s stock valued at $123,000 after buying an additional 6,362 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in Tocagen by 2,075.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 15,099 shares of the company’s stock valued at $155,000 after buying an additional 14,405 shares during the last quarter. Dowling & Yahnke LLC bought a new stake in Tocagen in the fourth quarter valued at about $169,000. Finally, Gamble Jones Investment Counsel bought a new stake in Tocagen in the fourth quarter valued at about $178,000. 32.63% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This report was first posted by Week Herald and is the property of of Week Herald. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://weekherald.com/2018/04/18/tocagen-toca-given-average-recommendation-of-buy-by-analysts.html.
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.